KOD

Kodiak Sciences Inc

Add to Watchlist

Advanced Chart

7.300

-0.5(-6.410%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.250

Open

7.910

VWAP

7.60

Vol

602.05K

Mkt Cap

385.17M

Low

7.190

Amount

4.57M

EV/EBITDA(TTM)

Total Shares

52.53M

246.32M

EV/OCF(TTM)

P/S(TTM)

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

-0.886

+5.46%

-0.971

+15.59%

-1.047

+21.71%

Estimates Revision

The market is revising No Change the revenue expectations for Kodiak Sciences Inc. (KOD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 62.58%.

EPS Estimates for FY2025

Revise Upward

+3.91%

In Past 3 Month

Stock Price

Go Up

+62.58%

In Past 3 Month

2 Analyst Rating

-52.05% Downside

Wall Street analysts forecast KOD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KOD is 3.50 USD with a low forecast of 3.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

1 Sell

Moderate Sell

-52.05% Downside

Current: 7.300

Low

3.00

Averages

3.50

High

4.00

-52.05% Downside

Current: 7.300

Low

3.00

Averages

3.50

High

4.00

HC Wainwright & Co.

Matthew Caufield

Hold

Reiterates

2025-03-31

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2025-03-31

Reiterates

Hold

Reason

Jefferies

Michael Yee

Hold

Strong Buy

Upgrades

$20

2024-12-09

Reason

Jefferies

Michael Yee

Price Target

$20

2024-12-09

Upgrades

Hold

Strong Buy

Reason

Jefferies upgraded Kodiak Sciences to Buy from Hold with a $20 price target.

HC Wainwright & Co.

Matthew Caufield

Hold

Reiterates

2024-11-15

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2024-11-15

Reiterates

Hold

Reason

Barclays

Gena Wang

Sell

Maintains

$3 → $4

2024-11-15

Reason

Barclays

Gena Wang

Price Target

$3 → $4

2024-11-15

Maintains

Sell

Reason

Barclays raised the firm's price target on Kodiak Sciences to $4 from $3 and keeps an Underweight rating on the shares. The firm says the company's Q3 highlighted recent progress and provided update across key pipeline programs.

HC Wainwright & Co.

Matthew Caufield

Hold

Reiterates

2024-09-24

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2024-09-24

Reiterates

Hold

Reason

HC Wainwright & Co.

Matthew Caufield

Hold

Initiates

2024-09-05

Reason

HC Wainwright & Co.

Matthew Caufield

Price Target

2024-09-05

Initiates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kodiak Sciences Inc (KOD.O) is -2.03, compared to its 5-year average forward P/E of -7.78. For a more detailed relative valuation and DCF analysis to assess Kodiak Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.78

Current PE

-2.03

Overvalued PE

2.84

Undervalued PE

-18.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.42

Current EV/EBITDA

-1.39

Overvalued EV/EBITDA

5.04

Undervalued EV/EBITDA

-17.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.93

Current PS

0.00

Overvalued PS

5.50

Undervalued PS

-3.64